$Relay Therapeutics (RLAY.US)$ Relay Therapeutics Announces ...
$Relay Therapeutics (RLAY.US)$ Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
3 MINUTES AGO, 6:55 AM EDT
VIA GLOBENEWSWIRE
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D
Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia
Data support planned initiation of 2L pivotal study in 2025
Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end
3 MINUTES AGO, 6:55 AM EDT
VIA GLOBENEWSWIRE
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D
Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia
Data support planned initiation of 2L pivotal study in 2025
Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
jimmy the trader :![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)